All News
ICYMI: Spondyloarthritis Innovations
The second day of RheumNow Live 2023 held in March ended with a focus on axial spondyloarthritis, especially on the evaluation of the definition of the disease, the inheritance of it, and of course the treatment of it.
Read Article
IL-6 for PMR
SPARE and SEMAPORE (Toci), SAPHYR (Sari)
2/2023: FDA approves sarilumab for PMR for inadequate response to corticosteroids or unable to taper off
Robert Spiera @RheumNow #RNL2023 https://t.co/gpBYXhguaV https://t.co/7tU1VBUb6F
Links:
Dr. John Cush RheumNow ( View Tweet)
Cochrane metanalysis of antidepressant use in managing chronic pain shows they dont work, with the small exception, duloxetine - at standard dose (60 mg) it was effective, but no benefit to using a higher doses https://t.co/SReueTu4VV https://t.co/ki0snBMS3z
Links:
Dr. John Cush RheumNow ( View Tweet)
"Ideally, you should get your TA biopsies within 2 weeks, but that's not always possible. Don't delay tx." @anisha_dua reminds us that bx can still be positive up to 8 weeks after steroid initiation. Just be aware of lesional changes with time. #RNL2023 https://t.co/uYBNrGzdQm https://t.co/Rvs0ewHzwb
Links:
Dr. John Cush RheumNow ( View Tweet)
Allergic Drug - Induced Arthritis
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow. This week we delve into some odd associations, repeat drug warnings and the consequences of antirheumatic therapies.
https://t.co/AmpWG2Siii https://t.co/PwEgVHfDu8
Links:
Dr. John Cush RheumNow ( View Tweet)
MSK Symptoms from Dupilimab, an IL-4/13 Inhibitor
A new MSK syndrome of inflammatory enthesitis/arthritis/tenosynovitis has been described in atopic dermatitis (AD) patients treated with the IL-4 receptor antagonist, dupilumab.
https://t.co/xGPSA2oRis https://t.co/y7M42DlM7d
Links:
Dr. John Cush RheumNow ( View Tweet)
Brepocitinib in Active PsA
Brepocitinib is a novel tyrosine kinase 2/JAK1 inhibitor and has been studied in patients with moderately-to-severely active psoriatic arthritis (PsA), showing impressive efficacy at both 16 weeks and 52 weeks.
https://t.co/qzOVsLMkYe https://t.co/ouLyB131r8
Links:
Dr. John Cush RheumNow ( View Tweet)
QD Clinic - Audience Vasculitis Questions from RNL23
Audience questions from the live RNL 2023 meeting and the session on EVOLUTION AND ADVANCES IN VASCULITIS held on March 18, 2023.
https://t.co/mvimbucTnd https://t.co/uJzkZcbNLa
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: TNR - Vasculitis: Evolution and Advances
This is a replay from the live RNL 2023 meeting and the session on EVOLUTION AND ADVANCES IN VASCULITIS held on March 18, 2023.
https://t.co/OAI8NbSNes https://t.co/eDqqV9yZ9d
Links:
Dr. John Cush RheumNow ( View Tweet)
TNF Inhibitors and Acne? A literature review found 47 refractory acne pts Rx w/ TNFi; noting partial improvement (94%) or clearance (40%) & only 6% w/ adverse events. 17 pts had new-onset acne after Rx w/ TNFi for a different inflamm Dx. Odd! https://t.co/duHEIHBMyK https://t.co/br8NQZQE2r
Links:
Dr. John Cush RheumNow ( View Tweet)
The Schwartzman's (Monica and Sergio) discuss being in rheumatology as a family unit. We are so lucky in rheumatology to have many family connections! #RNL2023 @RheumNow https://t.co/hFbeGll2ut https://t.co/dfHnnbpNS8
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr. Anisha Dua on Imaging in PMR:
- US of shoulders to eval for bursitis can increase specificity
- MRI better for pelvic girdle, but expensive
- Consider PET if lack of response to steroids, r/o malignancy
#RNL2023 @RheumNow https://t.co/tjhGlJPDWZ https://t.co/9h1FwfM0CP
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr. Langford's take home for GPA. Remember to consider disease severity (will determine tx,) maintenance tx, and non-medical management including vaccination options for pts. #RNL2023 @RheumNow https://t.co/R6nrz7YXZr https://t.co/UVY0jDUGJ2
Links:
Dr. John Cush RheumNow ( View Tweet)
Avacopan in GPA
- non-inferior to prednisone for induction remission
- received FDA approval for treatment of severe active GPA in combo with standard therapy and steroids
- should be used in newly diagnosed active or relapsing disease
@rheumnow #RNL2023 https://t.co/My6M5MGBl1 https://t.co/0aPFUeE55Q
Links:
Dr. John Cush RheumNow ( View Tweet)
How to long for maintenance of GPA?
Continue for 24 months, then consider:
Relapse history? Organ damage? Toxicity? Patient wishes? Compliance? Family planning?
Dr. Langford @RheumNow #RNL2023 https://t.co/tFn2p5DfJV https://t.co/Uu4Fmans40
Links:
Dr. John Cush RheumNow ( View Tweet)
U.S. FDA Approves RINVOQ® (upadacitinib) as a Once-Daily Pill for Moderately to Severely Active Crohn's Disease in Adults based on induction studies, U-EXCEED, U-EXCEL,& U-ENDURE maintenance study. This is 7th FDA approval for RINVOQ https://t.co/FypYaTMJxU https://t.co/yilppBv6Ka
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr. Carol Langford on GPA treatment
Duration of remission maintenance therapy?
- at least 2 years, after 2 years, maintenance appropriate in many cases
- consider RTX, and other cDMARDs (MTX, MMF, AZA)
@RheumNow #RNL2023 https://t.co/gAEo6SudES https://t.co/RGSzXy0vE5
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr. Langford #RNL2023
When to use CYC over RTX for severe GPA induction?
- Severe disease with RTX intolerance
- Worsening disease despite RTX
- RGPN Cr > 4.0, mechanical ventilation? (these were excluded from RAVE trial)
@RheumNow https://t.co/AnSAnGP6Oa https://t.co/iHF6tiFvj2
Links:
Dr. John Cush RheumNow ( View Tweet)
Carol Langford #RNL2023
Use of CYC + RTX:
Not routine upfront, but may be needed for escalating disease
Limited data to support initial usage
Higher risk of hypogammaglobulinemia, infection, and death
@RheumNow https://t.co/DRLf1Zl5bN https://t.co/fSv5ciAklI
Links:
Dr. John Cush RheumNow ( View Tweet)
Carol Langford #RNL2023 @RheumNow
Rx options for GPA showed by targeted to patient's disease characteristics of severe vs non-severe disease
CYC not for non-severe due to toxicity
MTX, MMF not for severe disease https://t.co/jw3wq2k7gb https://t.co/y3ck6KuCDj
Links:
Dr. John Cush RheumNow ( View Tweet)